Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain

We evaluated the efficacy and safety of lorlatinib in ALK- and ROS1-positive NSCLC patients within a compassionate use program in Spain. Among 61 ALK-positive patients, including 59 % with brain metastasis and 85.2 % treated with at least 2 prior ALK TKIs, lorlatinib achieved a confirmed overall response rate (ORR) of 32.8 % and a median progression-free survival (PFS) of 11.2 months. In 42 ROS1-positive patients previously treated with crizotinib, lorlatinib showed an ORR of 47.6 % and a median PFS of 10 months, confirming its clinical activity despite the lack of FDA or EMA approval for this indication.

Authors

Institutions

Publication Details

Journal
Cancer Treatment and Research Communications
Published
2025-01-01
DOI
https://doi.org/10.1016/j.ctarc.2025.100905
Citations
1
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain

Álvaro Taus, Èlia Sais, Natividad Martínez Madrid, Óscar Juan et al.
1 citations
Cancer Treatment and Research Communications
Lung Cancer Treatments and Mutations
1.52
article

Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain

Álvaro Taus, Èlia Sais, Natividad Martínez Madrid, Óscar Juan, Javier Baena, Xabier Mielgo-Rubio, Ernest Nadal, Paloma Martín-Martorell, Cristina Bayona, Carlos Aguado, Virginia Calvo, Marc Cucurull, Margarita Amenedo, Ana Isabel Santos, Santiago Aguín, E. Arriola, Joaquín Mosquera, Eider Azkona, Margarita Majem, Anna Estival, A Blasco, Maite Martínez-Aguillo, Dolores Isla, Javier de Castro, Ana Gómez‐Berrocal, Roxana Reyes, Antonio Calles, Ana Laura Ortega Granados, Andrés Aguilar, M Milagros Alonso, N. Villanueva, María Pilar Diz-Taín
article en
1 citations

Abstract

We evaluated the efficacy and safety of lorlatinib in ALK- and ROS1-positive NSCLC patients within a compassionate use program in Spain. Among 61 ALK-positive patients, including 59 % with brain metastasis and 85.2 % treated with at least 2 prior ALK TKIs, lorlatinib achieved a confirmed overall response rate (ORR) of 32.8 % and a median progression-free survival (PFS) of 11.2 months. In 42 ROS1-positive patients previously treated with crizotinib, lorlatinib showed an ORR of 47.6 % and a median PFS of 10 months, confirming its clinical activity despite the lack of FDA or EMA approval for this indication.

Cancer Treatment and Research CommunicationsVol. 43
Universidad de Las Palmas de Gran Canaria (ES), Universidade de Santiago de Compostela (ES), Instituto Cajal (ES), Universitat de Girona (ES), Hospital Universitario Insular de Gran Canaria (ES), Hospital Universitario La Paz (ES), Hospital de Sant Pau (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital Clínico San Carlos (ES), Research Institute Hospital 12 de Octubre (ES), Institut d'Investigació Biomédica de Bellvitge (ES), Hospital Madre Teresa (BR), Clínica Girona (ES), Hospital Clínico Universitario de Valencia (ES), Hospital Universitario Dexeus (ES), Complejo Hospitalario Universitario de Santiago (ES), Centro Oncológico de Galicia (ES), Hospital Universitario Fundación Alcorcón (ES), Hospital Universitario 12 De Octubre (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Hospital Clínic de Barcelona (ES), Hospital Universitario de Burgos (ES), Complejo Hospitalario de Jaén (ES), Hospital General Universitario De Valencia (ES), Hospital Del Mar (ES), Hospital Universitario Central de Asturias (ES), Hospital Clínico Universitario Lozano Blesa (ES), Badalona Serveis Assistencials (ES), Hospital de Cruces (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Hospital Universitario Puerta del Mar (ES), Instituto de Investigación Sanitaria de Santiago (ES), Hospital Municipal de Badalona (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Universitario Ramón y Cajal (ES), Complejo Hospitalario Universitario de Toledo (ES), Complejo Asistencial Universitario de Palencia (ES), Instituto de Investigación Sanitaria La Fe (ES), Universidad de Burgos (ES), Universidad de Navarra (ES)
Good health and well-being
Openalex Percentile: Top 21%
Lung Cancer Treatments and Mutations
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.